EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) mutations are the most commonly observed mutations in non-small cell lung cancer and EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) are used as the primary treatment [30].